reports
Shareholders of Evolva Holding SA in liquidation approve BoD proposals...
Evolva Holding SA / Key word(s): AGMEGM Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected 12.04.2024 / 19:10 CET/CEST PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Shareholders of Evolva Holding SA in liquidation approve proposals put forward by the Board of Directors at Annual General Meeting; of the three agenda items put forward by Nice & Green, revocation of the liquidation and the delisting were also approved whereas introduc...
Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG...
Evolva Holding SA / Key word(s): Takeover Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023 28.12.2023 / 17:45 CET/CEST PRESS RELEASE Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023 Reinach, Switzerland, 28 December 2023 — Following the approval on 21 December 2023 by the shareholders of Evolva Holding AG (SIX: EVE) of the sale of Evolva AG to Danstar Ferment AG, a Swiss affiliate of Lallemand Inc., the parties have successfully closed the transaction on 28 December 2023. Evolva Holding S...
Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss sub...
Evolva Holding SA / Key word(s): AGMEGM Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting 21.12.2023 / 17:45 CET/CEST PRESS RELEASE Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting Reinach, 21 December 2023 — The shareholders of Evolva Holding SA (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, approved all the proposals put forward by the Board of Directors at today’s extraordinary general meeting (EGM). The sharehol...
Evolva and Breko broaden partnership by signing agreement for the excl...
Evolva Holding SA / Key word(s): Agreement Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTM Resveratrol in Germany, Austria, Thailand and Vietnam 14.11.2023 / 07:00 CET/CEST PRESS RELEASE Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTMResveratrol in Germany, Austria, Thailand and Vietnam Reinach, 14 November 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, and Breko GmbH, Bremen, Germany (“Breko”), a leading supplier of p...
Evolva shareholders approve increase of the conditional capital and up...
Evolva Holding SA / Key word(s): AGMEGM Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023 24.08.2023 / 20:00 CET/CEST PRESS RELEASE Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023 Reinach, 24 August 2023 — The shareholders of Evolva Holding SA (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, approved the proposals put forward by the Board of Direct...
Evolva receives approval for Veri-teTM Resveratrol in Taiwan
Evolva Holding SA / Key word(s): Regulatory Approval Evolva receives approval for Veri-teTM Resveratrol in Taiwan 25.07.2023 / 07:00 CET/CEST PRESS RELEASE Evolva receives approval for Veri-teTM Resveratrol in Taiwan Reinach, 25 July 2023 – Evolva (SIX: EVE) a pioneer in the field of natural molecules and industrial biotech, has received approval for its Veri-teTM Resveratrol from the Taiwanese Food and Drug Administration (TFDA) for use as an ingredient in foods and dietary supplements. The approval is an important milestone as it opens up Taiwan as a further South-East...
Evolva publishes timeline of the Reverse Stock Split
Evolva Holding SA / Key word(s): AGMEGM Evolva publishes timeline of the Reverse Stock Split 24.04.2023 / 07:00 CET/CEST Reinach, 24 April 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, today communicates on the timeline of the reverse stock split of 250:1 which was approved by shareholders at the Annual General Meeting on 18 April 2023 by a large majority: 25 April 2023: Last trading day of old shares on SIX Swiss Exchange 26 April 2023: First trading day of new shares on SIX Swiss Exchange (ex-date) The reverse split of...
Evolva shareholders approve all motions proposed by the Board at today...
Evolva Holding SA / Key word(s): AGMEGM Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting 18.04.2023 / 17:30 CET/CEST Press Release (PDF) The shareholders approved, among others: The Reverse stock split of 250:1, followed by a reduction of the par value of the shares to CHF 1.00 Introduction of a capital band of up to +/- 20% of current share capital Re-election of all board members and election of Stephan Schindler as Chairperson, ensuring continuity in the Board Reinach, 18 April 2023 — Evolva (SIX: EVE), a pioneer in the ...
Evolva goes Responsible Care at in-cosmetics 2023
Evolva Holding SA / Key word(s): Product Launch Evolva goes Responsible Care at in-cosmetics 2023 28.03.2023 / 07:00 CET/CEST PRESS RELEASE Evolva is globally launching an exclusive line of nature-based high-purity ingredients and bio-functionals for the personal care industry, produced in a sustainable manner New science backed up by proprietary research studies by Evolva unlock an innovative spectrum of cosmetic claims for topical skin and scalp applications This enables customers to create differentiated consumer experiences with proven effects for skin and hair be...
Evolva launches its Natural Nootkatone
Evolva Holding SA / Key word(s): Market launch Evolva launches its Natural Nootkatone 14.12.2022 / 07:00 CET/CEST Reinach, 14 December 2022 – Evolva (SIX: EVE) a pioneer in the field of natural molecules and industrial biotech, is lauching “Natural Nootkatone by Evolva”, a natural ingredient at the highest purity level now meeting all requirements to be qualified as natural also in the EU, in addition to the US. This broadens Evolva’s existing Nootkatone offering and opens up significant new addressable markets based on naturality and sustainability. Nootkatone is an ing...
Evolva statement to SER communication
Evolva Holding SA / Key word(s): Statement Evolva statement to SER communication 12.12.2022 / 06:45 CET/CEST Sanctions Commission of SIX Group followed Evolva’s main arguments Addressed deficiencies are related to incomplete disclosures and technical mistakes related to the goodwill impairment tests in the financial reporting in 2019 and 2020 Key allegations were not upheld No impact on past P&L and balance sheets nor on future business case New management team has strengthened internal processes and rules Reinach, 12 December 2022 – Evolva (SIX: EVE), a pioneer in th...
Evolva: Update on activities to boost Resveratrol
Evolva Holding SA / Key word(s): Product Launch Evolva: Update on activities to boost Resveratrol 29.11.2022 / 07:00 CET/CEST Reinach, 29 November 2022 – Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, today provides an update on the ongoing activities to boost the commercial performance of Resveratrol sales under its umbrella brand “Veri-teTM Resveratrol”. First successes have been achieved in the core market segment of dietary supplements, among others by the signing of a new distribution agreement and the successful Menopause Campaign laun...
Evolva receives approval for Veri-teTM Resveratrol for animal health i...
Evolva Holding SA / Key word(s): Regulatory Approval Evolva receives approval for Veri-teTM Resveratrol for animal health in Brazil 10.11.2022 / 07:01 CET/CEST Reinach, 10 November 2022 – Evolva (SIX: EVE) a pioneer in the field of natural molecules and industrial biotech, has received approval for its Veri-teTM Resveratrol from the Brazilian Ministry of Agriculture, Livestock and Supply for animal nutrition and health, covering all animal species and all applications, including veterinary supplements. The approval is an important milestone as it opens up exciting oppor...
Evolva receives grant from US CDC in the amount of USD 540,000
Evolva Holding SA / Key word(s): Miscellaneous Evolva receives grant from US CDC in the amount of USD 540,000 21.10.2022 / 07:00 CET/CEST Reinach, 21 October 2022 – Evolva (SIX:EVE) a pioneer in the field of natural molecules and industrial biotech, has received a grant of USD 540,000 from the US Centers for Disease Control and Prevention (CDC) for the development of NootkaSHIELDTM for new formulations and applications in the area of tick bite prevention. The grant will be distributed in several payments over a period of 18 months, commencing on 30 September 2022. The g...
Evolva’s NootkaSHIELDTM insect repellent approved in Hong Kong
Evolva Holding SA / Key word(s): Product Launch Evolva’s NootkaSHIELDTM insect repellent approved in Hong Kong 11.10.2022 / 07:00 CET/CEST Reinach, 11 October 2022 – Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, has received approval for its NootkaSHIELDTM concept from the Hong Kong regulatory authorities as an active ingredient for use in insecticides and insect repellents. The initial market launch of an application as personal repellent spray is targeted for the first quarter of 2023. The registration in Hong Kong is an importan...
Evolva business update: Continued good business momentum
Evolva Holding SA / Key word(s): 9 Month figures Evolva business update: Continued good business momentum 06.10.2022 / 07:00 CET/CEST 3Q 2022 revenues more than tripled compared to 3Q 2021 Year-to-date revenues by end of September already 56% ahead of the same period last year Gross contribution margin further increased in 3Q 2022 On track to reach full-year 2022 targets of CHF 15 million in revenues and a double-digit gross contribution margin Reinach, 6 October 2022 – Evolva (SIX:EVE), a pioneer in the field of natural molecules and industrial biotech, today provid...
Evolva statement to SER communication
Evolva Holding SA / Key word(s): Miscellaneous Evolva statement to SER communication 23.08.2022 / 06:45 Evolva takes note of the sanction request submitted by SIX Exchange Regulation (SER) today Alleged deficiencies concern the goodwill impairment tests in the financial reporting 2019 and 2020 and related disclosures Evolva is convinced that key allegations do not uphold and that potential deficiencies do not have a material impact No impact on cash position and business case New management team has strengthened internal processes and rules Reinach, 23 August 2022 –...
- Kate Heseltine
Evolva - Evolving the sales model
Evolva has signed a distribution agreement to jointly develop the Brazilian market for resveratrol with its new partner, Tovani Benzaquen, a distributor of food and functional ingredients. Management expects revenues to exceed CHF1.5m over the next 2.5 years. The distribution agreement opens the Brazilian market for resveratrol, thus should result in an uplift in revenue expectations for the product. If successful, we believe the distribution agreement could be extended to other markets in Latin...
Evolva shareholders approve all proposed resolutions at the Annual Gen...
Evolva Holding SA / Key word(s): AGMEGM Evolva shareholders approve all proposed resolutions at the Annual General Meeting 2022 05.05.2022 / 18:05 PRESS RELEASE Reinach, May 05, 2022 – Shareholders of Evolva (SIX:EVE), a pioneer in the field of natural molecules and industrial biotech, approved all proposals put forward by the Board of Directors at Evolva's Annual General Meeting (AGM) 2022 by large majority. Beat In-Albon, Chairman of Evolva, comments on the successful conclusion of the AGM: “We thank our shareholders for their ongoing support and for the approval of al...
- Kate Heseltine
Evolva - Shareholder-friendly AGM proposals
Evolva has announced changes to its Board of Directors at its upcoming AGM. Richard Ridinger, who joined the board two years ago, is not standing for re-election given his other commitments, but will continue to support Evolva in an advisory role. Two new members are being proposed, bringing the total number of board members to five and broadening the board’s experience. Evolva is also proposing to increase the existing conditional and authorised share capital to allow for strategic and financia...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.